ABGI

ABG Acquisition Corp. I

 

상장예정일: 2월 17일

타겟 : 헬스케어

운영진 : Frank Yu (Founder/CEO, Ally Bridge Group)

규모 : $131M

 

 

요약

 

General

We are a newly incorporated blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare-related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value.

Our sponsor is an affiliate of Ally Bridge Group, a global healthcare-focused investment group founded by Fan (Frank) Yu with dual-headquarters in New York and Hong Kong. Mr. Yu and his team began their track record of successful healthcare investing in 2011 in China and have since become global healthcare investors with a strong U.S. focus. ABG currently manages or advises over $2.5 billion in healthcare assets, with a portfolio of what we believe to be some of the world’s most novel life science companies and technologies based in the United States, Europe and China. ABG primarily focuses on high-impact investments in cutting-edge life science innovations in the U.S. across the medtech, tools and diagnostics, biopharmaceutics and, increasingly, digital health and telemedicine sectors. ABG has successfully invested through the following strategies: i) venture; ii) private equity, including buyout and growth capital; and iii) public equity.

 

 

Venture—investing in innovative life science companies at early to developmental stages, primarily in the U.S., with a focus on innovative drugs, medical devices and diagnostics.

 

Buyout and large growth capital—investing in cash flow-generating life science companies in the U.S., China and Europe. ABG leverages its unique strengths in capital markets, M&A, global investing, and cross-border deal-making, deal execution, business development and partnerships.

 

 

Public equity—employing a fundamental bottom-up, research-driven, as well as proactive and value-adding, approach to investing in public equities, initially in Asia and now primarily in the U.S.

 

 

ABG’s investment experience across various financing stages (from early- to late-stage), types of companies (from private to public), the innovative life science spectrum (e.g., medtech, tools and diagnostics, biopharma and digital health) and three of the world’s key healthcare markets (i.e., the U.S., China and Europe) represents a competitive edge of the Sponsor.

ABG’s strategy is to focus on generating superior risk/reward outcomes through private-to-public market value creation and cross-border value-add and arbitrage. Since 2011, Mr. Yu and his team have completed approximately $1 billion in healthcare investments (including private equity and private investment in public equities, or PIPEs) for the funds they manage or advise. Significant transactions include the $3.3 billion take-private of WuXi Pharmatech from the New York Stock Exchange (“NYSE”) and private investments in companies such as Atea Pharmaceuticals (Nasdaq: AVIR), Tesaro (Nasdaq: TSRO, acquired by GlaxoSmithKline), GRAIL (being acquired by Illumina) and Pulmonx (Nasdaq: LUNG). ABG typically leads or co-leads its private investments.

 

 

 

www.sec.gov/cgi-bin/browse-edgar?CIK=1833764

EDGAR Search Results